be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Lycored Launches Video to Support Study Findings
Lycored, industry leaders in cultivating we...
Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Molecular Biology and Immunology of Cancer – R&D perspectives: ScanBalt Forum 2019, 24-25 September, Gdańsk (Poland)
Inaugural EU-MED Summit held in Lodz will drive innovation and bring new opportunities to the healthcare ecosystem

All articles

Filters:

Show search box

2013-11-12

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Merck, one of the leaders in production of pharmaceuticals, put its new medicine under review. It is called vintafolide, MK-8109 and it is an injectable drug conjugate consisting of folate (vitamin B9) linked to alkaloid chemotherapy agent, desacetylvinblastine monohydrazine (DAVLBH). ... Read more

Tags medicine , cancer , Merck , MSD , cancer targetting